重药控股预计前三季度净利3.58亿元至4亿元，同比预增22.51%—36.88%

Core Viewpoint - Zhongyao Holdings (重药控股) expects a net profit attributable to shareholders of approximately 358 million to 400 million yuan for the first three quarters of 2025, representing a year-on-year growth of 22.51% to 36.88% [1] Group 1: Financial Performance - The company anticipates a net profit of about 3.58 billion to 4 billion yuan for the first three quarters of 2025 [1] - This projected profit growth is attributed to a steady increase in revenue driven by the development of various business segments including pharmaceuticals, medical devices, traditional Chinese medicine, specialty pharmacies, and emerging businesses [1] Group 2: Business Strategy - Zhongyao Holdings has been continuously improving its network layout, which has contributed to stable revenue growth [1] - The company has implemented refined management practices to enhance operational efficiency, leading to cost reduction and increased effectiveness [1]